fda enforcement intelligence
Just got a Warning Letter?
Proving ongoing FDA monitoring is usually part of the remediation story from here. Argus is a daily FDA Warning Letter brief matched to your company, your competitors, and your CDMOs — so the next one doesn’t catch your team off-guard.
the offer
30 days free. No card.
$199/mo after your trial. Cancel any time before then and you’re never charged.
One 3-question survey after signup (industry, CDMOs, competitors) sets your watchlist. Your first brief lands the same day.
No card today, no sales call ever. Cancel from Settings in one click before day 30 and you owe nothing — if you stay on past the trial, the same 30-day money-back guarantee covers you.
what you get
- Daily brief, 6am ET. Every FDA Warning Letter that matches your industries, named competitors, and CDMOs — summarized, severity-tagged, source-cited.
- Trend pulse. Which issuing offices and citation types are trending up across your therapeutic area, so your next internal audit targets the right SOPs.
- Audit-ready export. A monthly artifact documenting that regulatory monitoring is in place — useful evidence in a remediation file.
Every summary links back to the verbatim fda.gov Warning Letter on the same line, so you can verify in seconds — this isn’t a replacement for your counsel or your QMS, it’s the monitoring layer that gets the right letter in front of the right person before it becomes a surprise.
Argus HQ is informational only. Summaries are AI-generated and may contain errors. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice. Verify any Warning Letter detail against the original on fda.gov.